The role of somatostatin analogs in the management of immunoproliferative disease

J Endocrinol Invest. 2003;26(8 Suppl):103-8.

Authors

D Ferone¹, M Arvigo, C Semino, R Pivonello, P M van Hagen, A Barreca, F Minuto

Affiliation

¹ Department of Endocrinological and Metabolic Sciences, University of Genova, Italy. [email protected]

PMID: 15233223

No abstract available

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents, Hormonal / therapeutic use*
Humans
Immunoproliferative Disorders / diagnosis
Immunoproliferative Disorders / drug therapy*
Immunoproliferative Disorders / metabolism
Lymphocytes / metabolism*
Lymphoma, Non-Hodgkin / drug therapy
Lymphoma, Non-Hodgkin / metabolism
Lymphoma, Non-Hodgkin / physiopathology
Lymphoproliferative Disorders / diagnosis
Lymphoproliferative Disorders / drug therapy
Lymphoproliferative Disorders / metabolism
Lymphoproliferative Disorders / physiopathology
Radiopharmaceuticals
Rats
Receptors, Somatostatin / metabolism*
Somatostatin / analogs & derivatives*
Somatostatin / therapeutic use
Tissue Distribution

Substances

Antineoplastic Agents, Hormonal
Radiopharmaceuticals
Receptors, Somatostatin
Somatostatin